684 results on '"Kleinschnitz C"'
Search Results
2. Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants
3. Animal models of ischemic stroke and their application in clinical research
4. VP71 Exploring the construct validity and reliability of sensor-based measurements derived from active motor assessments in adult walkers with SMA
5. Thromboinflammatory challenges in stroke pathophysiology
6. Postvirale Erkrankungen – die Neurologie sollte Farbe bekennen
7. P11.14.A Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2021
8. OS06.5.A Investigating safety and efficacy of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma - the PriCoTTF phase I/II trial
9. P17.04.B Combination of Trofosfamide and Etoposide in Recurrent Glioma
10. P11.15.B First multicentric real-life experience with the combination of lomustine and temozolomide in newly diagnosedMGMT promoter methylatedIDH wildtype glioblastoma
11. Genetisch basierte Therapien bei spinaler Muskelatrophie
12. Auftreten einer Stand‑, Gang- und Atemstörung nach respiratorischem Infekt
13. EP06* The subarachnoid hemorrhage early brain edema score (SEBES) as radiographic marker of clinically relevant intracranial hypertension and unfavorable outcome after subarachnoid hemorrhage
14. Acid sphingomyelinase deactivation post-ischemia/ reperfusion promotes cerebral angiogenesis and brain remodeling via small extracellular vesicles
15. 34/m mit chronischem Muskelschwund
16. Health‐related quality of life in patients with untreated cavernous malformations of the central nervous system
17. Measuring Outcomes in Adults with Spinal Muscular Atrophy – Challenges and Future Directions – Meeting Report
18. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy
19. Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
20. Die Vordere Augenkammer: Eintrittsstelle von Gadolinium in das ZNS?
21. Is Histologic Thrombus Composition in Acute Stroke Linked to Stroke Etiology or to Interventional Parameters?
22. Neurological examination course in an interactive webinar as a solution during a pandemic. An overview of the implementation, optimization as well as critical considerations
23. Multiple Sklerose: selektive Wirkung von Teriflunomid auf T‑Zellen
24. P14.61 Tumor Treating Fields (TTFields) combined with lomustine (CCNU) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) patients - a bi-centric analysis
25. Intrathekale Nusinersentherapie bei Erwachsenen mit spinaler Muskelatrophie: Machbarkeit und Sicherheit
26. Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy
27. Detection of early infarction signs with machine learning-based diagnosis by means of the Alberta Stroke Program Early CT score (ASPECTS) in the clinical routine
28. Gerinnungsfaktoren und Multiple Sklerose: Schlüsselfaktoren in der Pathogenese?
29. Neue Horizonte – Das Darmmikrobiom als Pathogenesefaktor bei der Myasthenia gravis
30. Dosimetrie bei erwachsenen Patienten mit spinaler Muskelatrophie unter Therapie mit Nusinersen bei CT-gesteuerter Therapie sowie unter Durchleuchtung, in Abhängigkeit von klinischen und anatomischen Faktoren
31. Gute Ernährung reduziert MS-Symptome
32. P01.060 PriCoTTF: a phase I/II trial of Tumor Treating Fields prior and concomitant to radiotherapy in newly diagnosed glioblastoma
33. P01.012 Tumor Treating Fields (TTFields) in combination with lomustine (CCNU) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)
34. Dimethylsulfoxide and Retinoic Acid-Induced Differentiation and Commitment in HL-60 Cells
35. 3132Casein Kinase 2 is a critical regulator of platelet Ca2+ signaling and activation in arterial thrombosis
36. Coagulation Testing in Intracerebral Hemorrhage Related to Non-vitamin K Antagonist Oral Anticoagulants
37. „Time is brain“ bei der schubförmigen Multiplen Sklerose: Aktuelle Behandlungskonzepte in der Immuntherapie
38. Intrathecal Resiniferatoxin Modulates TRPV1 in DRG Neurons and Reduces TNF-Induced Pain-Related Behavior
39. Neues beim Schlaganfall
40. „Time is brain“ bei der schubförmigen Multiplen Sklerose: Aktuelle Behandlungskonzepte in der Immuntherapie
41. Artificial intelligence for the differentiation between multiple sclerosis and glioma II° or III° using 18F-FET-PET imaging
42. Platelets and vascular inflammation of the brain
43. SFRR-E Young Investigator AwardeeNOXing out stroke: Identification of NOX4 and 5as targets in blood-brain-barrier stabilisation and neuroprotection
44. Casein kinase 2Β is critical player in platelet activation, arterial thrombosis and ischemic stroke: OR114
45. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
46. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
47. Munc13‐4‐mediated secretion is essential for infarct progression but not intracranial hemostasis in acute stroke
48. SFRR-E Young Investigator AwardeeNOXing out stroke: Identification of NOX4 and 5 as targets in blood-brain-barrier stabilisation and neuroprotection: OP2-5
49. Experimentelle Ansätze zur Therapie des ischämischen Schlaganfalls
50. Akuter ischämischer Schlaganfall: Neue Ansätze in der Antithrombosetherapie
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.